FA (Fanconi anaemia) is a hereditary disease characterized by congenital malformations, progressive bone marrow failure and an extraordinary elevated predisposition to develop cancer. In the present manuscript we describe an anomalous high level of the proinflammatory cytokine IL-1β (interleukin-1β) present in the serum of FA patients. The elevated levels of IL-1β were completely reverted by transduction of a wild-type copy of the FancA cDNA into FA-A (FA group A) lymphocytes. Although the transcription factor NF-κB (nuclear factor-κB) is a well established regulator of IL-1β expression, our experiments did not show any proof of elevated NF-κB activity in FA-A cells. However, we found that the overexpression of IL-1β in FA-A cells is related to a constitutively activated PI3K (phosphoinositide 3-kinase)-Akt pathway in these cells. We provide evidence that the effect of Akt on IL-1β activation is mediated by the inhibition of GSK3β (glycogen synthase kinase 3β). Finally, our data indicate that the levels of IL-1β produced by FA-A lymphoblasts are enough to promote an activation of the cell cycle in primary glioblastoma progenitor cells. Together, these results demonstrate that the constitutive activation of the PI3K-Akt pathway in FA cells upregulates the expression of IL-1β through an NF-κB-independent mechanism and that this overproduction activates the proliferation of tumour cells.
INTRODUCTION
FA (Fanconi anaemia) is a rare recessive genetic disease characterized by congenital malformations, high chromosomal fragility, progressive bone marrow depletion and a striking susceptibility to develop cancer [1] . The disease is genetically heterogeneous and is caused by mutations in at least 13 different genes that correspond to 13 different complementation groups. Nine of these proteins aggregate in response to damage in the DNA and monoubiquitinate the protein FANCD2 (FA complementation group D), which then relocalizes into the points of damage together with other DNA repair proteins. However, not every aspect of the cellular FA phenotype could be explained through the formation of this nuclear complex. A growing amount of evidence points to a role of FANCC and FANCA in the signal transduction pathways leading to the inhibition of apoptosis and the promotion of cell survival [2] [3] [4] . Mutation analysis of FANCC identified different domains responsible for its separated nuclear and cytoplasmic functions [5] . The deficiency in different FANC proteins has been associated with alterations in the activation of several transduction pathways [2, 6, 7] . A large effort has been made to discover alterations leading to the haematological problems of these patients. However, further investigation is needed to fully understand the molecular basis for the cancer propensity of FA. Several groups, including ours, are trying to approach this problem by defining a molecular profile of the genes transcriptionally altered in FA. Interestingly, the expression profile of FANCC-deficient cells unveiled an unsuspected antiinflammatory role for the FA proteins [8] . In line with this, other authors have reported an exacerbated inflammatory response in FANCC-deficient mice [9] . In addition, TNFα (tumour necrosis factor α), a well known pro-inflammatory cytokine, has been shown to be oversecreted in FA patients [10] . All these observations suggest that some cytokines and immune modulators may help explain the clinical features of FA patients, including bone marrow failure and increased tumour susceptibility.
The association between chronic inflammation and cancer has been known for some time and is supported by animal models [11] [12] [13] . IL (interleukin)-1β and TNFα are two of the best known pro-inflammatory cytokines. The secretion of IL-1β by tumours has been associated with a more aggressive phenotype and poor outcome [14] . Consistent with this, tumours actively producing IL-1β grow faster, are more metastatic, promote tumour angiogenesis and more easily elude the immune response [15] . Furthermore, IL-1β transgenic mice, or mice bearing a targeted deletion of the IL-Ra gene that codes for the naturally occurring antagonist of the IL-1β receptor, show an increased incidence of tumours [16, 17] .
FA patients of the group A, FA-A, are the most abundant among the FA patients. However, there is very little literature regarding the role of cytokines or other modulators of the immune and inflammatory response in this group of patients. Our massive gene expression studies showed that IL-1β is the most prevalent overexpressed gene in FA-A cells. In addition, we studied the molecular mechanisms leading to this overexpression and present in vitro evidence for the activity of the IL-1β secreted by FA-A cells in tumour cell proliferation.
EXPERIMENTAL

Cell culture and ELISA analysis
Peripheral blood mononuclear cells were obtained from healthy donors and FA patients after informed consent had been obtained. This research was carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association, and was approved by the Hospital Marqués de Valdecilla Ethics Committee for Clinical Research of Cantabria. To determine the complementation group of these patients, cells were transduced with retroviral vectors expressing FANCA, FANCC, FANCF or FANCG proteins (provided by H. Hanenberg, Department of Pediatric Oncology, Hematology and Immunology, Children's Hospital, Heinrich-Heine University, Dusseldorf, Germany) and then exposed to increasing concentrations of MMC (mitomycin C). EBV (Epstein-Barr virus)-transformed lymphoblasts from FA-A patients and healthy donors were maintained in RPMI medium (Biochrom, Berlin, Germany) supplemented with 10 % heat-inactivated FCS (fetal calf serum) and antibiotics. Cells were grown in the presence of LY294002 (Alexis) or BAY 11-7082 (Sigma) where indicated and the amount of IL-1β and TNFα in the culture medium was determined by ELISA (BD Biosciences) following the manufacturer's instructions. The same ELISA assay was used to determine the amount of IL-1β in the serum of the blood samples obtained from FA patients and healthy donors after informed consent had been obtained.
RT (reverse transcription)-PCR analysis
Total RNA was prepared using TRI reagent (MRC, Cincinnati, OH, U.S.A.). To assess mRNA expression, a semiquantitative RT-PCR method was used. For the RT reaction, RNA (10 μg) was primed with random hexamers and reverse transcribed with Superscript MMLV reverse transcriptase (Invitrogen) in a 20 μl volume following the manufacturer's instructions. The generated cDNA was amplified using primers for human IL-1β (5 -TCATTGCTCAAGTGTCTGAAGC and 5 -TGG-TCGGAGATTCGTAGC), FancA (5 -GCTCTTCAGGAATC-TGTGCTGC and 5 -TACAGTGAGGTGAGCAGAGG), A1 (5 -CGGATGTGGATACCTATAAGG and 5 -GTCATCCAGCCA-GATTTAGG), IAP1 (5 -TGAGCATGCAGACACATGC and 5 -TGACGGATGAACTCCTGTCC), XIAP (5 -TGGCAATA-TGGAGACTCAGC and 5 -TGCACTTGGTCACCAATACC) , Bcl-2 (5 -AGATGTCCAGCCAGCTGCACCTGAC and 5 -AGA-TAGGCACCCAGGGTGATGCAAGCT) and β2μ (β2-microglobulin) (5 -GAGACATGTAAGCAGCATCA and 5 -AGCAA-CCTGCTCAGATACAT). After 30 amplification cycles, except for β2μ (25 cycles), the expected PCR products were sizefractionated onto a 2 % agarose gel and stained with ethidium bromide.
Western blot analysis
To prepare whole cell lysates, cells were collected by centrifugation and washed once with PBS and then lysed in EBC buffer (50 mM Tris/HCl, pH 8.0, 120 mM NaCl and 0.5 % Nonidet P40) supplemented with aprotinin (11.5 μg/ml), leupeptin (11.5 μg/ml) PMSF (50 μg/ml), NaF (100mM) and sodium orthovanadate (0.2 mM). Protein concentration was determined using BCA (bicinchoninic acid) following the manufacturer's instructions (Pierce). Proteins (100 μg) were resolved in SDS/PAGE and transferred to PVDF filters. Blots were incubated with rabbit antibodies against proIL-1β (Santa Cruz), phospho-Akt (Ser 473 ), Akt (Cell Signaling, Danvers, MA, U.S.A.) or mouse anti-α-tubulin antibody (Sigma) and then incubated with goat anti-rabbit or anti-mouse antibodies conjugated with horseradish peroxidase (Pierce). Bound antibody was detected using a chemiluminescence assay (Pierce).
EMSA (electrophoretic mobility-shift assay)
Nuclear protein extracts were obtained from different cell lines as previously described [18] . The nuclear extracts (5-10 μg of total protein) were incubated on ice for 15 min with 1 μg of poly(dI-dC) (Pharmacia) in 2.5 % glycerol, 10 mM Tris/HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 1 mM PMSF and 0.5 μg/ml of BSA. Antibodies or competitor oligonucleotides were added during this incubation. Upon addition of 100 000 c.p.m. of the 32 P-labelled doublestranded DNA probe from the promoter region of the IL-1β gene containing an NF-κB (nuclear factor-κB)-responsive element (5 -GTAACGTGGGAAAATCCAGTATT), the reaction mixture was incubated for 15 min on ice and then resolved on a 5% polyacrylamide gel run at 25 mA for 2.5 h. The gel was dried and exposed to X-ray film.
Co-cultures and cell cycle analysis
125 000 glioblastoma progenitor cells were plated in 6-well plates and cultured in DMEM (Dulbecco's modified Eagle's medium)-Ham's medium supplemented with 2 % B27, 20 ng/ml EGF (epidermal growth factor), 20 ng/ml bFGF (basic fibroblast growth factor) and 180 units/ml heparin overnight. Co-culture canisters were then set on the corresponding wells containing 10 6 FA-A lymphoblasts in the same medium, in the presence or absence of 75 μg/ml of IL-1Ra. One of the wells was cultured in the presence of 20 ng/ml of recombinant IL-1β as a control. After 36 h, the glioblastoma stem cells were harvested and their cell cycle was analysed by propidium iodide staining on a flow cytometer.
Gene reporter assay
A genomic PCR fragment of 990 bp (base pairs) (− 950 to + 40, referred to the initiation of transcription) from the 5 regulatory region of IL-1β (IL-1β − 950 kb) was amplified with specific primers and cloned into the pGL2basic luciferase reporter vector (Promega). Deletions of this original construct were obtained by amplification using specific primers and cloning into pGL2basic. HCT116 cells were cotransfected with 2 μg of pGL2-IL-1β constructs and 0.1 μg of pRSV-β-gal in triplicate using Lipofectamine TM (Invitrogen) according to the manufacturer's instructions. At 36 h after transfection, cell extracts were prepared and analysed for their luciferase activity by using a reporter gene assay system (Promega). Results were normalized for transfection efficiency with the β-galactosidase activity values obtained in the same extracts.
RESULTS
IL-1β is overexpressed in FA patients
Our lab has focused on the study of the gene expression profile of FA cells responsible for their characteristic phenotype. In order to have a global picture of this expression profile, we carried out a high throughput analysis of RNA obtained from primary blood samples of FA-A patients (RNA from three The same ELISA analysis as in (E) was used to detect the IL-1β levels in the serum of FA patients of the indicated complementation groups. The IL-1β levels in eight control serum levels were analysed in parallel.
different FA patients and three healthy age-matched persons were analysed independently with Affymetrix U133 Genechip arrays). This analysis revealed several inflammatory cytokines overexpressed in FA-A mononuclear blood cells. IL-1β was the most overexpressed gene in FA mononuclear cells, 15-fold higher than the healthy counterparts ( Figure 1A ). IL-8 (7.35-fold) and interferon γ (4.81-fold) were also overexpressed in FA-A cells. Interestingly, the array analysis did not show any increase in TNFα mRNA in FA-A cells, although TNFα-interacting protein 3 showed a 4.18-fold higher expression compared with healthy donors. Since IL-1β was the most overexpressed gene in FA-A blood cells, we focused our studies on this cytokine. As shown in Figure 1 (B), the semiquantitative RT-PCR analysis confirmed a significant accumulation of IL-1β mRNA in FA-A primary samples compared with the control counterparts. We also wanted to check the expression of this cytokine in the EBV-immortalized B-lymphoblast cell lines derived from FA-A patients that we normally use in our studies. IL-1β is synthesized as an immature molecule, pro-IL-1β, that is digested by caspase-1 to produce its active form, which is then secreted into the medium. Interestingly, the microarray analysis showed a reduced caspase 1 mRNA accumulation in FA-A cells (2.4 mean fold reduction relative to control cells, see Figure 1A ). We analysed whole cell extracts for the pro-IL-1β level in FA-A lymphoblastoid cell lines. The Western blot analysis revealed a 33 kDa band corresponding to pro-IL-1β of increased intensity in FA-A cell lines ( Figure 1D ). Moreover, the secreted IL-1β levels in the growing medium of FA-A lymphoblasts were also elevated as analysed by ELISA ( Figure 1E ). In order to extend our findings to the patients, we analysed serum samples obtained from patients of different complementation groups. Thus, a total of 17 serums from 12 FA-A patients, two FA-D2, two FA-G and one FA-J patients, were analysed. Ten out of 12 FA-A patients studied showed an increase in IL-1β secretion above the mean value obtained from eight controls. Notably, all of the non-A FA patient samples contained an increased level of IL-1β ( Figure 1F ). Overall, these data demonstrate an elevated IL-1β secretion in FA-A patients, most likely due to a transcriptional process since the messenger stability does not seem to be altered (Figure 2A ). 
NF-κB does not seem to be involved in the overexpression of IL-1β in FA-A lymphoblasts
As stated previously, NF-κB is a main regulator of IL-1β expression. A constitutive activation of NF-κB in FA-A lymphoblasts was then conceivably responsible for the overexpression of IL-1β. We tested this possibility by analysing the expression of other NF-κB target genes in these cells. Figure 3(A) shows that A1, IAP1, Bcl2 or XIAP genes are expressed at similar levels in control and FA cells. We then tested the binding of NF-κB to a consensus probe in an EMSA assay, as a measure of its activation in FA cells. NF-κB bound more weakly to its consensus binding sequence in FA lymphoblasts than in their control counterparts, suggesting a lower level of activation of the NF-κB pathway ( Figure 3B ). Similar results were found in FA-A fibroblasts (results not shown). In addition to this, we observed that the treatment of FA-A lymphoblasts with BAY 11-7082, a specific inhibitor of the NF-κB pathway, did not inhibit the accumulation of the IL-1β mRNA in those cells ( Figure 3C ). We also tested a possible alteration in the NF-κB-responsive element of the IL-1β gene in FA-A cells that may affect its transcription. However, sequencing of a fragment of the 5 regulatory region embracing the NF-κB element at position − 290 [19] cloned from FA-A lymphoblasts or control cells showed no differences (results not shown). All these observations rule out a functional overactivation of the NF-κB in FA-A lymphoblasts. We decided to investigate other possible pathways regulating IL-1β transcription. MAPK (mitogen-activated protein kinase)/SAPK (stress-activated protein kinase) are kinases with a known influence in the expression and secretion of IL-1β. However, neither the ERK (extracellular-signal-regulated kinase) nor the JNK (c-Jun N-terminal kinase) pathways show an increase in their basal activity in FA-A lymphoblasts, as we have previously reported [2] . An analysis of the phosphorylation status of ERK in these cells with specific anti-phospho antibodies confirmed our previous results (results not shown). All these observations made us discard an involvement of the ERK or JNK pathways in the overexpression of IL-1β in FA-A cells.
The PI3K-Akt signaling pathway is crucial to many aspects of cell growth and survival, especially in cells under stress conditions. We analysed the phosphorylation status of Akt in whole cell extracts from FA-A lymphoblasts with an antiphospho-Ser 473 -Akt antibody. The Western blot analysis depicted in Figure 4 (A) shows that Akt phosphorylation was undetectable in control lymphoblasts whereas it was strongly activated in FA-A lymphocytes. This activation was reverted, at least in part, in FA-A lymphoblasts cultured in the presence of 20 μM LY294002, an inhibitor of PI3K. More importantly, when FA-A lymphoblasts were phenotypically reverted by transduction of the FancA cDNA, the phosphorylation of Akt was clearly reduced (Figure 4B ), supporting the idea that the deficiency in the FANCA protein is responsible for the constitutive activation of Akt in FA lymphoblasts. To test if the activated PI3K-Akt pathway is related to the overexpression of IL-1β in FA-A lymphoblasts, we analysed the expression of IL-1β in cells grown in the presence of increasing doses of LY294002. As shown in Figure 4 (C), the treatment with LY294002 induced a dose-dependent reduction of the IL-1β mRNA expression in FA-A lymphoblasts, almost completely reverting its overexpression. Consistent with this, the IL-1β secreted by these cells was also reduced in the presence of the inhibitor ( Figure 4D ). These results demonstrate an involvement of the PI3K-Akt pathway in the overexpression of IL-1β in FA-A lymphoblasts.
Inhibition of GSK3β (glycogen synthase kinase 3β) by constitutively activated Akt1 in FA-A lymphoblasts mediates IL-1β overexpression
Among the different proteins regulated by Akt phosphorylation, the inhibitory kinase GSK3 attracted our attention because of its known role in the regulation of transcription factors involved in IL-1β gene expression. Whole cell extracts from lymphoblasts were analysed by Western blotting with an anti-phospho-Ser 9 -GSK3 antibody. As seen in Figure 5 (A), both control and FA-A cell lines showed similar phosphorylation levels of GSK3α, but GSK3β was clearly more phosphorylated in FA-A cells at Ser 9 , suggesting an inhibition of GSK3β by Akt1 phosphorylation in these cells. In order to confirm a functional inhibition of GSK3 by Akt1 in FA-A lymphoblasts, we analysed whether the phosphorylation of GSK3 in these cells affects the stability of the β-catenin protein. The Western blot depicted in Figure 5 (A) shows that inhibition of GSK3 in FA-A lymphoblasts is actually followed by an increase in the levels of β-catenin.
To the best of our knowledge, no reports have described an effect of GSK3 on the modulation of IL-1β gene expression. To test if IL-1β is actually regulated by GSK3, we treated control lymphoblasts with increasing doses of Li + , a known inhibitor of GSK3 function [20] . Inhibition of GSK3 function by Li + in control lymphoblasts induced a dose-response increase in IL-1β mRNA accumulation, reaching the levels observed in FA-A lymphoblasts ( Figure 5B ). In order to provide more evidence supporting this observation, we transfected a dominant-negative form of GSK3β [21] carrying an inactivating mutation in the ATPbinding site (GSK3β-K85A) into control lymphoblasts. The dominant-negative transfected cells showed a noticeable increase in the expression of IL-1β mRNA compared with the empty vector-transfected cells, further confirming the regulation of the expression of this gene by GSK3β (Figures 5C and 5D ). We also tested the activation of a transfected luciferase construct containing 950 bp of the 5 regulatory region of the IL-1β gene in response to the inhibition of GSK3. We chose HCT116 cells for their high transfection efficiency. Li + induced a 2-fold increase in the IL-1β promoter activity in these cells ( Figure 5E ). Deletion of the region between positions − 350 and − 150 decreased the basal activity to half, but the − 150 construct was still activated by Li + . However, deletion from position − 150 to − 100 produced a profound decrease in the induction by GSK3β inhibition of the IL-1β regulatory region ( Figure 5E ). These are the first observations indicating that GSK3β is able to modulate the expression of IL-1β by the inhibition of its transcription, and suggests the loss of this repression as the mechanism mediating the overproduction of IL-1β in FA-A lymphoblasts.
The IL-1β produced by FA-A cells is functionally active
We then asked whether the IL-1β levels produced by our FancAdeficient cells were enough to promote the growth of cancer cells. To this end, we cultivated primary glioblastoma progenitor cells with FA lymphoblasts separated by a semipermeable membrane, and analysed the activation of NF-κB. There have been reported mutations in FANC proteins in a percentage of spontaneous gliomas, so we thought this primary tumour could be suitable for these experiments [22] . EMSA experiments showed an increased binding to the NF-κB probe in nuclear extracts of glioblastoma cells co-cultivated with FA-A lymphoblasts ( Figure 6A ). Thus the IL-1β produced by FA lymphoblasts activates a well known pathway involved in survival and proliferation in glioblastoma progenitor cells in vitro. Similar results were obtained with extracts obtained from the myeloblastic leukemia cell line HL60 co-cultured with FA-A lymphoblasts (results not shown).
To prove that the IL-1β levels produced by FA lymphoblasts are enough to induce proliferation of cancer cells, we analysed the cell cycle of the primary glioblastoma progenitor cells co-cultured with FA-A lymphoblast. We detected an increase in the number of cells entering mitosis from 5.3 % to 8.3 %, similarly to when glioblastoma cells were grown in the presence of 20 ng/ml of IL-1β (from 5.3 % to 9.8 %) ( Figure 6B , compare panels 1 and 2 with panels 3-5). In order to assess that this effect is due to the IL-1β produced by the FA-A lymphoblasts, we added the naturally occurring IL-1β competitor, IL-1Ra, to the co-culture medium. The addition of IL-1Ra decreased the number of glioblastoma cells entering mitosis from 8.3 % to 6.7 % (Figure 6B , compare panels 5 and 6), and this matched with a reduction in the activation of NF-κB in the cells (Figure 6A) , demonstrating that the increase in proliferating glioblastoma cells was due to IL-1β produced by the FA-A cells. A similar activation in cell cycle was observed when HL60 cells were used in the co-culture experiments ( Figure 6C ).
To further investigate the functionality of the IL-1β levels produced by the FA lymphoblasts, we used an oral squamous cell carcinoma cell line derived from FA patients (EUFA1365) [23] in the same kind of co-culture experiments. The main solid tumour affecting FA patients is squamous cell carcinoma, so the use of this cell line that also bears a mutation in the FancA gene is of special interest to study the effect of IL-1β in its growth rate. We found a 1.6-fold increase in the percentage of EUFA1365 cells entering mitosis when co-cultured with FA-A lymphoblasts compared with the same cells cultured in the presence of control lymphoblasts ( Figure 6D ). These results support the in vitro functional activity of the IL-1β levels produced by FA lymphoblasts.
DISCUSSION
FA is characterized by a progressive bone marrow depletion and an extraordinary predisposition to develop cancer. It has been reported that the depletion of haematopoietic precursors is due to their high predisposition to enter into apoptosis in response to cytotoxic cytokines or environmental stresses. However, much less attention has been paid to the study of the susceptibility of FA patients to develop cancer. Several groups, including ours, have reported a role of FANC proteins seperate from the role in the cellular nucleus. It is now clear that at least some FANC proteins play a role in the cytoplasm, in pathways involved in the response to cytokines and the development of a response to insults against the DNA or the cell homoeostasis [2, 6, 7] . In the present manuscript we describe the overproduction of IL-1β in FA-A patients by a mechanism involving the PI3K-Akt signalling pathway. The levels of IL-1β produced by FA-A cells are capable of inducing proliferation in cancer cells in vitro, thus providing support for a possible role of IL-1β in the progression of cancer in these patients.
IL-1β and TNFα are considered 'alarm' cytokines since they are not normally expressed in health but they are rapidly induced in inflammation. In this respect, our data are consistent with previous reports describing an excessive production of TNFα by FA-A cells [10] , since it is generally believed that both cytokines should be regulated in the same way. Indeed, cytokine-detection experiments carried out in our laboratory showed a great increase in both secreted cytokines, IL-1β and TNFα, when measured in the growth medium of FA-A lymphoblasts, in comparison with the levels secreted by control cells (results in the present manuscript and not shown). However, when we analysed the mRNA levels, TNFα showed a discrete elevation with respect to control cells (results not shown), supporting a post-translational effect of FANC deficiency in its overproduction, and explaining why we could not detected alterations in TNFα in the array analysis. On the other hand, the IL-1β mRNA expression was strikingly elevated not only in FA lymphoblast cell lines, but also in primary T-cells and the whole mononuclear fraction obtained from FA patients blood samples, suggesting a transcriptional effect of the FANCA protein defect on IL-1β expression.
Several transcription factors have a functional response element in the promoter of the IL-1β gene, including NF-κB, C/EBPβ (CCAAT/enhancer-binding protein β), Spi1 and HSF (heat shock factor)-1 [19, [24] [25] [26] . Probably the best known of all these is NF-κB, due to the important role that this factor has in inflammation. We then wanted to test whether or not this factor was constitutively active in FA-A lymphoblasts. We used three different approaches to analyse it. Our results discount a constitutive activation of NF-κB in FA-A lymphoblasts as responsible for IL-1β overexpression. In this respect, it has been recently reported that NF-κB is actually a negative regulator of IL-1β secretion [27] . These results contrast with the observations of Briot et al. [28] , which suggest a constitutive activation of the NF-κB pathway in FANCC-deficient cells. These two opposite groups of results may indicate distinct roles for individual FANC proteins in the cytoplasm and provide a possible explanation of the variations in the phenotype of different FA complementation groups that cannot be attributable to their co-operative role in the nuclear FA-BRCA (breast-cancer susceptibility gene) protein complex. Interestingly, the patients we analysed from other complementation groups (FA-D2, FA-G and FA-J) also showed very high levels of IL-1 in their blood serum. At the present time, we do not have an explanation for this observation and further analysis of a bigger group of patients would be necessary to confirm and interpret these data correctly.
Our experiments with inhibitors of different signalling pathways showed a normalizing effect of LY294002 over the elevated levels of IL-1β protein and mRNA in FA-A cells, and indeed, we detected an accumulation of activated Akt in these cells, suggesting a role of PI3K-Akt activation in FA cell phenotype. This may also explain the lack of activation of JNK in response to DNA damage in these cells [2] , since phosphoAkt is known to repress the phosphorylation of JNK by ASK1 (apoptosis signal-regulating kinase 1) [29] . Moreover, phosphoAkt activates Mdm2 (murine double minute 2) protein, which affects the levels of p53 protein, targeting it for degradation [30] . We have previously shown the reduced p53 protein levels in FA-A lymphoblasts with no correlation to the accumulation of its mRNA [31] . All these previous observations match with our present description of a constitutively active PI3K-Akt pathway in FA-A cells.
When investigating the possible pathways connecting the constitutively active Akt to the IL-1β overexpression in FA cells, we began to study GSK3. This kinase phosphorylates and inhibits several transcription factors, some of them known regulators of IL-1β expression. Interestingly, the genetic disruption of the GSK3β gene abrogates the activation of JNK, NF-κB and ERK, but potentiates the apoptosis induced by TNFα, a hallmark of FA cells [32] . GSK3 also phosphorylates β-catenin, labelling it for degradation. β-Catenin has a prominent role in certain tumours, being essential in the maintenance of the stem phenotype of the cutaneous cancer cells [33] . Interestingly, there is evidence for the role of β-catenin signalling in squamous cell carcinomas, the major solid tumour affecting FA patients [33] . All these observations pointed to GSK3-altered phosphorylation as a mediator of the FA phenotype. To the best of our knowledge, this is the first time it has been reported that the transcription of the IL-1β gene is regulated by the PI3K-Akt-GSK3β pathway. Several putative response elements for transcription factors known to be regulated by GSK3β lie within the 5 regulatory region of the IL-1β gene. We are now focusing on the identification of the transcription factor/s mediating the overexpression in FA cells. Alternatively, β-catenin may play an important role in IL-1β overproduction in FA cells, by means of its interaction with members of the Tcf/Lef family of transcription factors. The analysis of all of the multiple possibilities was beyond the scope of the present work.
IL-1β overexpression in FA patients could be a risk factor in the development of more agressive neoplasias. Several groups have reported the involvement of this cytokine in the carcinogenic process, promoting tumour growth, inhibiting apoptosis and diminishing the immunological response against the tumour [34] . Although this article does not show direct interaction of the FANCA protein with any member of the PI3K-Akt pathway, previous observations support an interaction between FANCA and Akt1 [35] . We are trying to confirm such an interaction in our cells and determine its influence in the functional activation of the PI3K-Akt pathway. In summary, the present study reports an overproduction of IL-1β in FA-A patients and provides strong evidence of a constitutively active PI3K-Akt-GSK3β pathway responsible for the IL-1β gene overexpression in FA-A cells, that can also explain many other aspects of the cellular FA phenotype. 
